VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

C. abortus DNA vaccine encoding CAB613
Vaccine Information
  • Vaccine Name: C. abortus DNA vaccine encoding CAB613
  • Target Pathogen: Chlamydophila abortus
  • Target Disease: Abortion and fetal death
  • Vaccine Ontology ID: VO_0011527
  • Type: DNA vaccine
  • Status: Research
  • Antigen: C. abortus CAB613 putative peptidase
  • CAB613 putative peptidase gene engineering:
    • Type: DNA vaccine construction
    • Description: To create the library of genetic immunization plasmids, genomic DNA of C. abortus strain B577 was physically sheared and cloned into the genetic immunization vector pCMVi-UB, which drives transcription using the strong mammalian CMV promoter (Stemke-Hale et al., 2005).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pCMVi-UB DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Doses of 50 μg library DNA were delivered intramuscularly to the quadriceps and tibialis anterior muscles. Doses of 2.5 μg DNA were delivered to the ear skin of mice with a gene gun. C. abortus B577 was grown in BGMK cells and titrated for IFU in BGMK shell vial coverslip cultures by enumeration of chlamydial inclusions stained with FITC-labeled monoclonal antibody against chlamydial LPS. For rounds 1 and 2 of ELI, mice were boosted 9 weeks after the prime inoculation in the same manner, and for rounds 3 and 4 of ELI the mice were given an additional boost 5 weeks after the prime (Stemke-Hale et al., 2005).
  • Challenge Protocol: In all cases, mice were challenged at 13 weeks with a dose of 3 × 106 inclusion forming units (IFU) of C. abortus administered intranasally. The positive control group representing protection received a low dose intranasal inoculation of 3 × 104 IFU of the same live strain four weeks prior to the high-dose challenge (Stemke-Hale et al., 2005).
  • Efficacy: Genetic immunization was used to functionally test the genes of C. abortus as vaccines in a mouse challenge system. Of the 14 individually tested clones, CP #1 through CP #9 had positive relative protection scores. CP #8 (CAB613, Oligopeptidase) was found to confer protection (Stemke-Hale et al., 2005).
References
Stemke-Hale et al., 2005: Stemke-Hale K, Kaltenboeck B, DeGraves FJ, Sykes KF, Huang J, Bu CH, Johnston SA. Screening the whole genome of a pathogen in vivo for individual protective antigens. Vaccine. 2005; 23(23); 3016-3025. [PubMed: 15811648].